ERBB2 and breast cancer: In this sense, Iwamoto et al. [21] reported that the proportion of HER2-positive BC was 17% among “self-detected”, 15% among “screening-detected (asymptomatic)” and 15% among ‘‘screening-detected (symptomatic)’’.